Close Banner
Section Free  - CAP Smart Takes

01. Long-Term Effects of Methylphenidate on Sleep in Children and Adolescents With ADHD

Published on June 1, 2024 Certification expiration date: June 1, 2027

David R. Rosenberg, M.D.

Chair of the Department of Psychiatry & Behavioral Neuroscience - Wayne State University School of Medicine

Key Points

  • Sleep disturbances are common in children and adolescents with ADHD, regardless of medication use.
  • Long-term use of methylphenidate does not appear to worsen sleep in children and adolescents with ADHD.
  • Methylphenidate may actually improve sleep in children and adolescents with ADHD compared with those not treated with medication.

Free Downloads for Offline Access

  • Free Download Audio File (MP3)

Text version

Hi! David Rosenberg here for the Psychopharmacology Institute. In this CAP—or Child and Adolescent Psychiatry—Smart Take, we will take a very close look at the long-term effects of methylphenidate on sleep in children and adolescents with ADHD. This is crucial because stimulants, such as methylphenidate, are still the most commonly prescribed treatment for ADHD worldwide, and methylphenidate has been widely reported to be associated with sleep problems. However, as we learn more about ADHD, some of our prior misconceptions are being overturned. Namely, sleep patterns in ADHD seem to be disrupted whether or not a person is on medication or psychostimulants. In other words, ADHD itself, with or without medication, is clearly associated with significant and severe sleep disturbances. Therefore, in our clinical program, we always obtain a detailed pretreatment baseline sleep inventory and assessment of all of our patients with ADHD who require treatment before initiating that treatment.

Although this is critical, our experience of receiving numerous referrals and second opinions tells us that this is one of the most often overlooked and missed areas of baseline assessment in many busy primary care and psychiatry practices. This means that sleep assessments are often not done at baseline, which can obviously hinder accurate and precise identification of whether or not the stimulant or methylphenidate is causing sleep disturbances if you do not know the child or adolescent’s baseline sleep functioning.

This has really challenged prior thinking that what we once presumed was a key side effect of methylphenidate. Is it really a side effect? How common is it? Could it be that it rather reflects the illness itself? However, to date, there have been strikingly few studies looking at the long-term impact of methylphenidate and other psychostimulants on sleep disturbances. This article, in particular, is a real advancement because it conducted a 2-year naturalistic, prospective, pharmacovigilance multicenter study of over 100 participants. They included 3 groups:

  1. Children and adolescents with ADHD who were intending to start methylphenidate
  2. Children and adolescents with ADHD who were not intending to be treated with methylphenidate
  3. A non-ADHD control group

So, what did they find? First of all, and perhaps not surprisingly, the only group that showed a significant increase in sleep from baseline was the control group. There were no significant differences in sleep between children and adolescents treated with methylphenidate and children not treated with methylphenidate. The results showed that sleep problems are very common in ADHD. Still, there were no significant negative long-term effects on sleep observed in children treated with methylphenidate compared with children and adolescents with ADHD not treated with methylphenidate.

Interestingly, and in contrast to what we might have expected, there actually appeared to be possible improvement of sleep in children with ADHD treated long-term with methylphenidate. This is significant because it indicates that ADHD can have a severe and substantial negative impact on sleep quality. Contrary to previous beliefs, treating ADHD with medication like methylphenidate may actually help improve the sleep patterns of children and adolescents diagnosed with ADHD. Of course, some children might experience negative long-term sleep impacts from methylphenidate, which might not have been detectable in this group assessment. So, we always need to monitor each child individually and carefully, as no 2 children are the same and different children can experience different effects when treated with the same medication. It is also really important to assess for medication interactions, as many children with ADHD will be treated with more than 1 medication. It is important to take into account comorbidity, as many patients with ADHD have depression and anxiety, both of which can definitely impair sleep.

The bottom line, though, is that this is a highly complex area. What should be reassuring is that long-term use of methylphenidate does not appear to make sleep worse and may actually improve sleep compared with children and adolescents with ADHD not treated with medication. This underscores again how vital it is to conduct pretreatment sleep inventories and assessments before initiating treatment in children and adolescents with ADHD.

Abstract

Methylphenidate and Sleep Difficulties in Children and Adolescents With ADHD: Results From the 2-Year Naturalistic Pharmacovigilance ADDUCE Study

Alexander Häge, Kenneth K C Man, Sarah K Inglis, Jan Buitelaar, Sara Carucci, Marina Danckaerts, Ralf W Dittmann, Bruno Falissard, Peter Garas, Chris Hollis, Kerstin Konrad, Hanna Kovshoff, Elizabeth Liddle, Suzanne McCarthy, Antje Neubert, Peter Nagy, Eric Rosenthal, Edmund J S Sonuga-Barke, Alessandro Zuddas, Ian C K Wong , David Coghill , Tobias Banaschewski

Objective: Short-term RCTs have demonstrated that MPH-treatment significantly reduces ADHD-symptoms, but is also associated with adverse events, including sleep problems. However, data on long-term effects of MPH on sleep remain limited.

Methods: We performed a 2-year naturalistic prospective pharmacovigilance multicentre study. Participants were recruited into three groups: ADHD patients intending to start MPH-treatment (MPH-group), those not intending to use ADHD-medication (no-MPH-group), and a non-ADHD control-group. Sleep problems were assessed with the Children’s-Sleep-Habits-Questionnaire (CSHQ).

Results: 1,410 participants were enrolled. Baseline mean CSHQ-total-sleep-scores could be considered clinically significant for the MPH-group and the no-MPH-group, but not for controls. The only group to show a significant increase in any aspect of sleep from baseline to 24-months was the control-group. Comparing the MPH- to the no-MPH-group no differences in total-sleep-score changes were found.

Conclusion: Our findings support that sleep-problems are common in ADHD, but don’t suggest significant negative long-term effects of MPH on sleep.

Free Files
Success!
Check your inbox, we sent you all the materials there.

Reference

Häge, A., Man, K. K., Inglis, S. K., Buitelaar, J., Carucci, S., Danckaerts, M., Dittmann, R. W., Falissard, B., Garas, P., Hollis, C., Konrad, K., Kovshoff, H., Liddle, E., McCarthy, S., Neubert, A., Nagy, P., Rosenthal, E., Sonuga-Barke, E. J., Zuddas, A., … Banaschewski, T. (2024). Methylphenidate and sleep difficulties in children and adolescents with ADHD: Results from the 2-Year naturalistic Pharmacovigilance ADDUCE studyJournal of Attention Disorders, 28(5), 699-707. 

Table of Contents

Learning Objectives:

  1. Recognize that long-term methylphenidate treatment of children and adolescents with ADHD may possibly improve sleep.
  2. Recognize the potential of deep transcranial magnetic stimulation as a novel treatment for treatment-resistant depression in adolescents.
  3. Recognize that, in adolescents, aripiprazole use may be associated with nonalcoholic steatohepatitis.
  4. Appreciate the importance of accurate diagnosis of primary conditions and comorbidities in achieving therapeutic efficacy and treatment response in youth with insomnia.
  5. Understand the role of antipsychotic treatment, particularly second-generation antipsychotics, in managing early-onset schizophrenia.

Original Release Date: June 1, 2024

Expiration Date: June 1, 2027

Experts: David Rosenberg, M.D.

Medical Editor: Lorena Rodriguez, M.D.

Relevant Financial Disclosures: 

None of the faculty, planners, and reviewers for this educational activity have relevant financial relationships to disclose during the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Contact Information: For questions regarding the content or access to this activity, contact us at support@psychopharmacologyinstitute.com

Instructions for Participation and Credit:

Participants must complete the activity online during the valid credit period that is noted above.

Follow these steps to earn CME credit:

  1. View the required educational content provided on this course page.

  2. Complete the Post Activity Evaluation for providing the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credit.

  3. Download your certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians

Credit Designation Statement

Medical Academy designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Free Files
Success!
Check your inbox, we sent you all the materials there.
Continue in the website
Instant access modal

Become a Silver, Gold, Silver extended or Gold extended Member.

2025–26 Psychopharmacology CME Program

Unlock up to 155 CME Credits, including 40 SA CME Credits.